Navigation Links
CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
Date:6/23/2009

Accreditation is designed to preserve the safety and integrity of the pharmaceutical supply chain

WOBURN, Mass., June 23 /PRNewswire/ -- CutisPharma, Inc. announced today that it has received Verified Accredited Wholesale Distributors (VAWD) accreditation from the National Association of Boards of Pharmacy (NABP) for its Woburn, Massachusetts facility. In March 2007 the company received accreditation for its Beverly facility. The NABP developed VAWD in response to the Food and Drug Administration's (FDA) Counterfeit Drug Task Force findings and recommendations. Applicants undergo a thorough criteria compliance review, licensure verification, employee background checks, screening through the NABP Clearinghouse and a comprehensive on-site inspection conducted by NABP experts.

CutisPharma is a specialty pharmaceutical company that develops and commercializes FIRST(R) Unit-of-Use Prescription Compounding Kits. The Company distributes its own private label products to National Wholesalers, Regional Distributors and Chain Drug stores. "We are pleased to receive our second VAWD accreditation from the National Association of the Boards of Pharmacy," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our participation in the accreditation program further demonstrates our commitment towards providing quality prescription pharmaceutical products to our customers."

CutisPharma currently has nine proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. The Company plans on introducing three new prescription mouthwash products this fall, and several more compounding kits are in the planning stages. FIRST(R) Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter (795).

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at www.cutispharma.com

About NABP

NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.

For more information about NABP or NABP's VAWD program, visit NABP's website at http://www.nabp.net


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... In a list ... out of the state’s 76 fastest-growing private companies; a small percentage of the state's ... ranked organizations on the percent change in revenue from 2012 to 2015. ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... addition of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently ... as Corporate Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... NeuroTech NYC , the sensor and data driven conferences, will take place on June 7-8, ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, ...
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
Breaking Biology News(10 mins):